Compare MPV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | PBYI |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | MPV | PBYI |
|---|---|---|
| Price | $18.60 | $5.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 25.2K | ★ 398.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 1.71 | 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.35 | ★ $7.56 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.18 | $2.58 |
| 52 Week High | $16.42 | $6.12 |
| Indicator | MPV | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 57.60 |
| Support Level | $18.00 | $5.48 |
| Resistance Level | $20.21 | $5.73 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 27.15 | 70.37 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.